small molecule

MILPROSA

PROGESTERONE

Loss of exclusivityJanuary 2030latest FDA-listed patent expiry
CompanyFerring PharmaceuticalsView the full company profile on CliffBio

Drug detail

Brand nameMILPROSA
Active ingredientPROGESTERONE
Strength1.78GM
Dosage formSYSTEM
RouteVAGINAL
ModalitySmall molecule
FDA approvalApril 2020
Marketing statusDISCN

Listed patents

PatentExpiresType
8580293January 2030use U-2810
10548904February 2029use U-2810
10537584February 2029product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MILPROSA patent cliff — loss of exclusivity January 2030 | CliffBio